


SRM

FGCZ

23 October 2017

Distribution of qValues



Histogram of qValues for all SRM assays. The red line indicates the qValue threshold - we control the False Discovery Rate (fdr) at this level.

Remove all transitions with more than X missing values

Histogram showing the number of missing values for the heavy peptides in all samples. The red line indicates the maximum of NA's allowed.

Histogram showing the number of missing values for the light peptides in all samples. The red line indicates the maximum of NA's allowed.




Figure 1: Distribution of NA's for heavy peptides




Figure 2: Distribution of NA's for light peptides.




Figure 3: Missing values $\log_2(L/H)$ per Transtion.

Heatmap of log₂(L/H)

Transitions dropped because of too many NA's in log₂ fold change.

Table 1: removed transitions (too many NA's)

Peptide.Sequence	Protein.Name	Precursor.Charge	Product.Charge	Fragment.Ion
AEGAGDAK	sp P05204 HMG2 HUMAN	2	1	y4
AEGAGDAK	sp P05204 HMG2 HUMAN	2	1	y6
AEGAGDAK	sp P05204 HMG2 HUMAN	2	1	y7
APEQEQAAPGPAAGGEAPK	sp P80723-1 BASP1 HUMAN	3	2	y9
CSFQDLDCPLDGGIQLR	sp P01584 IL1B HUMAN	3	1	y7
CSFQDLDCPLDGGIQLR	sp P01584 IL1B HUMAN	3	1	y9
CSFQDLDCPLDGGIQLR	sp P01584 IL1B HUMAN	3	2	y9
DDKPTLQLESVDPK	sp P01584 IL1B HUMAN	3	1	y5
DDKPTLQLESVDPK	sp P01584 IL1B HUMAN	3	1	y6
DDKPTLQLESVDPK	sp P01584 IL1B HUMAN	3	1	y7
DPAFTALLTTQTQVQR	sp P54108 CRIS3 HUMAN	2	1	y7
FALITWIGENVSGLQR	sp Q14019 COTL1 HUMAN	3	1	y5
FALITWIGENVSGLQR	sp Q14019 COTL1 HUMAN	3	1	y7
FYQLPSNQYQSTR	sp P22894 MMP8 HUMAN	2	1	b4
FYQLPSNQYQSTR	sp P22894 MMP8 HUMAN	2	1	y5
FYQLPSNQYQSTR	sp P22894 MMP8 HUMAN	2	1	y6
FYQLPSNQYQSTR	sp P22894 MMP8 HUMAN	2	2	y9
GFSGTPGSNENSTQNVYK	sp Q9NP99-1 TREM1 HUMAN	2	1	b5
GFSGTPGSNENSTQNVYK	sp Q9NP99-1 TREM1 HUMAN	2	1	y2
GFSGTPGSNENSTQNVYK	sp Q9NP99-1 TREM1 HUMAN	2	1	y4
GFSGTPGSNENSTQNVYK	sp Q9NP99-1 TREM1 HUMAN	2	2	y13
GNFHAVYR	sp P05109 S10A8 HUMAN	2	1	y2
GNFHAVYR	sp P05109 S10A8 HUMAN	2	1	y5
GNFHAVYR	sp P05109 S10A8 HUMAN	2	2	y5
GNPTVEVDLFTSK	sp P06733-1 ENOA HUMAN	2	1	y3
GNPTVEVDLFTSK	sp P06733-1 ENOA HUMAN	2	1	y6
GNPTVEVDLFTSK	sp P06733-1 ENOA HUMAN	2	1	y8
IILEDYHDHGLLR	sp Q9NP99-1 TREM1 HUMAN	3	2	y11
IQNLLPDDSVSTTR	sp P48595 SPB10 HUMAN	2	1	y7
LGNGVQCLAMGWLLGR	sp P08246 ELNE HUMAN	2	1	y8
NLYLSCVLK	sp P01584 IL1B HUMAN	2	1	y6
NLYLSCVLK	sp P01584 IL1B HUMAN	2	1	y7
NSHPVQVGR	sp Q9NP99-1 TREM1 HUMAN	2	1	b3
NSHPVQVGR	sp Q9NP99-1 TREM1 HUMAN	2	1	y6
NSHPVQVGR	sp Q9NP99-1 TREM1 HUMAN	2	2	y6
NSHPVQVGR	sp Q9NP99-1 TREM1 HUMAN	2	2	y7
NYPENTYYSNFISHLANIK	sp P23280 CAH6 HUMAN	2	1	y7
QGNMATAALQAALK	sp O15511-1 ARPC5 HUMAN	2	2	y10
TYFPHFDLSHGSAQVK	sp P69905 HBA HUMAN	2	2	y12
TYLFLQEYLDIAIK	sp P29508-1 SPB3 HUMAN	2	1	y7
TYLFLQEYLDIAIK	sp P29508-1 SPB3 HUMAN	2	1	y8
VDVDEYDENK	sp O15511-1 ARPC5 HUMAN	2	1	y5
VDVDEYDENK	sp O15511-1 ARPC5 HUMAN	2	1	y6
VDVDEYDENK	sp O15511-1 ARPC5 HUMAN	2	1	y7
VDVVLGPIQLQTPPR	sp Q9UGM3-1 DMBT1 HUMAN	2	1	b3
VDVVLGPIQLQTPPR	sp Q9UGM3-1 DMBT1 HUMAN	2	1	b4

Peptide.Sequence	Protein.Name	Precursor.Charge	Product.Charge	Fragment.Ion
VDVVLGPIQLQTPPR	sp Q9UGM3-1 DMBT1 HUMAN	2	1	b5
VDVVLGPIQLQTPPR	sp Q9UGM3-1 DMBT1 HUMAN	2	2	y11
VFDEFKPLVEEPQNLIK	sp P02768-1 ALBU HUMAN	3	2	y5
VPAQSESVR	sp P50552 VASP HUMAN	2	1	y6
VPAQSESVR	sp P50552 VASP HUMAN	2	1	y7
VPAQSESVR	sp P50552 VASP HUMAN	2	2	y8
VQIYHNPTANSFR	sp P50552 VASP HUMAN	2	1	b6
VQIYHNPTANSFR	sp P50552 VASP HUMAN	2	1	y7
VQIYHNPTANSFR	sp P50552 VASP HUMAN	2	1	y8
VQIYHNPTANSFR	sp P50552 VASP HUMAN	2	2	y11
VTIAQGGVLPNIQAVLLPK	sp P0C0S8 H2A1 HUMAN	2	2	y10

Peptide Quantification

The following plots show $\text{Log}_2(\text{H}/\text{L})$ of peptides belonging to the same proteins (y axis) given samples (x axis). These fold changes will be used to compute the fold H/L fold change of the protein in a sample.

Remove all peptides with only one transition.

Table 2: peptides removed since only a single valid transition

Peptide.Sequence	Protein.Name	Precursor.Charge	Product.Charge	Fragment.Ion
FALITWIGENVSGLQR	sp Q14019 COTL1 HUMAN	3	1	y4
FYQLPSNQYQSTR	sp P22894 MMP8 HUMAN	2	1	b3
TYLFLQEYLDAIK	sp P29508-1 SPB3 HUMAN	2	1	b3
VDVVLGPIQLQTPPR	sp Q9UGM3-1 DMBT1 HUMAN	2	1	y3

Removing decorrelated

List of peptides removed

Peptides might have been removed since there were no quantified transtions, only a single transition was quantified or the transition were uncorrelated.

Table 3: All removed peptides.

Protein.Name	Peptide.Sequence	Precursor.Charge
sp P05204 HMG2 HUMAN	AEGAGDAK	2
sp P80723-1 BASP1 HUMAN	APEQEQAAPGPAAGGEAPK	3
sp P01584 IL1B HUMAN	CSFQDL DLCPLDGGIQLR	3
sp P01584 IL1B HUMAN	DDKPTLQLESVDPK	3
sp Q14019 COTL1 HUMAN	FALITWIGENVSGLQR	3
sp P22894 MMP8 HUMAN	FYQLPSNQYQSTR	2
sp Q9NP99-1 TREM1 HUMAN	GFSGTPGSNENSTQNVYK	2
sp P05109 S10A8 HUMAN	GNFHAVYR	2
sp P06733-1 ENO1 HUMAN	GNPTVEVDLFTSK	2
sp P01584 IL1B HUMAN	NLYLSCVLK	2
sp Q9NP99-1 TREM1 HUMAN	NSHPVQVGR	2
sp O15511-1 ARPC5 HUMAN	QGNMTAALQAALK	2
sp P29508-1 SPB3 HUMAN	TYLFLQEYLDAIK	2
sp O15511-1 ARPC5 HUMAN	VDVDEYDENK	2
sp Q9UGM3-1 DMBT1 HUMAN	VDVVLGPIQLQTPPR	2
sp P50552 VASP HUMAN	VPAQSESVR	2
sp P50552 VASP HUMAN	VQIYHNPTANSFR	2


List of peptides used for quantification

Table 4: Peptides Still available and Nr of transitions per peptide.
Columns charge state.


	2	3
AAQVTIQSSGTFSSK	3	0
AAYNLVR	3	0
AGFAGDDAPR	3	0
AGLQFPVGR	3	0
ALAAGGVGSIVR	3	0
ALDFAVGGEYNK	3	0
ALNSIIDVYHK	3	0
ALQVVR	3	0
ALTGHLEEVVLALLK	0	3
APEPHVEEDDDDELDSK	0	4
APNVVVTR	3	0
ASNDMYHSR	3	0
ASSIIDELFQDR	3	0
AVFPSIVGRPR	3	0
AVGLQLYYK	3	0
CVWDIEVQNNYR	4	0
DGAGDVAFIR	3	0
DNENVVNEYSSELEK	5	0
DPAFTALLTTQTQVQR	3	0
EDGGWWYNR	3	0
EILSVDCSTNNPSQAK	3	0
ELLALIQLER	3	0
ESEPQAAAEPAEAK	3	0
ETPAATEAPSSTPK	3	0
FCEAEFSVK	3	0
FFADLLDYIK	3	0
FGNADGAACHFPFIFEGR	0	3
FLASVSTVLTSK	3	0
FQNALLVR	3	0
GEELSCEER	3	0
GLGTDEDTLIEILASR	3	0
GVDEATHIDILTK	3	0
HLQLAIR	3	0
HVIEIHIVHYNSK	0	3
IGAEVYHNLK	3	0
ILEDYHDHGLLR	0	2
INLGFSNLK	3	0
IQNLLPDDSVDSTTR	4	0
LENSLLDHR	3	0
LFAFVR	3	0
LFSDPITVTVPVEVSR	4	0
LGNGVQCLAMGWLLGR	2	0
LLETECPQYIR	3	0
LSAKPAPPKPEPKPK	0	3
LTFINDLCGPR	3	0
NLFLSNVFK	3	0
NLLFNDNTECLAR	3	0

	2	3
NQGNTWLTAFVLK	3	0
NYPENTYYSNFISHLANIK	2	0
QDGSVDFGR	4	0
QGHNSVFLIK	0	3
QLAEEYLYR	3	0
QNCELFEQLGEYK	3	0
QSTLVLFPGDLR	3	0
QYTSFHFASLEDVQAK	0	3
SGAQATWTELPWPHEK	0	3
SISGAFFGIESK	3	0
SNLCALCIGDEQGENK	3	0
SNVCTLVR	3	0
SYELPDGQVITIGNER	3	0
TLLGDGPVVTDPK	3	0
TYFPHFDLSHGSAQVK	2	0
VFDEFKPLVEEPQNLIK	0	2
VGAHAGEYGAEALER	0	3
VIGGDDLSTLTGK	3	0
VLHFDQVTENTTGK	0	3
VLSSIEQK	3	0
VSVQLEASPAFLAVPVEK	4	0
VTIAQGGVLPNIQAVLLPK	5	0
VVLGAHNLSR	0	3
VWVYPPEK	3	0
WANQCNYR	3	0
YISPDQLADLYK	4	0
YLAEVATGDDK	3	0
YNQATPNFHQWR	0	3
YYAFDLIAQR	3	0
YYYVCQYCPAGNWANR	5	0

Peptide Intensities



Protein Intensities



List of quantified proteins

Table 5: Quantified proteins with number of peptides used for quantification

Protein	NrPeptides
sp O15511-1 ARPC5 HUMAN	1
sp P00492 HPRT HUMAN	2
sp P01023 A2MG HUMAN	3
sp P01034 CYTC HUMAN	3
sp P02675 FIBB HUMAN	3
sp P02768-1 ALBU HUMAN	3
sp P02790 HEMO HUMAN	3
sp P04083 ANXA1 HUMAN	3
sp P05109 S10A8 HUMAN	2
sp P05204 HMGN2 HUMAN	1
sp P06733-1 ENOA HUMAN	2
sp P08246 ELNE HUMAN	3
sp P0C0S8 H2A1 HUMAN	3
sp P10909-1 CLUS HUMAN	3
sp P14780 MMP9 HUMAN	3
sp P22894 MMP8 HUMAN	2
sp P23280 CAH6 HUMAN	3
sp P29508-1 SPB3 HUMAN	2
sp P31947-1 1433S HUMAN	3
sp P48595 SPB10 HUMAN	3
sp P50552 VASP HUMAN	1
sp P52566 GDIR2 HUMAN	3
sp P54108 CRIS3 HUMAN	3
sp P68032 ACTC HUMAN	3
sp P69905 HBA HUMAN	3
sp P80723-1 BASP1 HUMAN	2
sp Q14019 COTL1 HUMAN	2
sp Q16610-1 ECM1 HUMAN	3
sp Q9NP99-1 TREM1 HUMAN	1
sp Q9UGM3-1 DMBT1 HUMAN	2
zz ZZ FGCZCont0031	3


List of proteins not quantified

proteins



sp|P01584|IL1B|HUMAN

Peptide profiles per Protein



sp|O15511-1|ARPC5|HUMAN





sp|P00492|HPRT|HUMAN





sp|P01023|A2MG|HUMAN





sp|P01034|CYTC|HUMAN





sp|P02675|FIBB|HUMAN





sp|P02768-1|ALBU|HUMAN





sp|P02790|HEMO|HUMAN




sp|P04083|ANXA1|HUMAN





sp|P05109|S10A8|HUMAN





sp|P05204|HMG2|HUMAN





sp|P06733-1|ENOA|HUMAN





sp|P08246|ELNE|HUMAN





sp|P0C0S8|H2A1|HUMAN





sp|P10909-1|CLUS|HUMAN




sp|P14780|MMP9|HUMAN




sp|P22894|MMP8|HUMAN





sp|P23280|CAH6|HUMAN





sp|P29508-1|SPB3|HUMAN




sp|P31947-1|1433S|HUMAN





sp|P48595|SPB10|HUMAN





sp|P50552|VASP|HUMAN





sp|P52566|GDIR2|HUMAN





sp|P54108|CRIS3|HUMAN





sp|P68032|ACTC|HUMAN





sp|P69905|HBA|HUMAN





sp|P80723-1|BASP1|HUMAN




sp|Q14019|COTL1|HUMAN





sp|Q16610-1|ECM1|HUMAN





sp|Q9NP99-1|TREM1|HUMAN





sp|Q9UGM3-1|DMBT1|HUMAN




zz|ZZ|FGCZCont0031|




Peptides used for quantification and their transitions




sp|P00492|HPRT|HUMAN_VIGDDLSTLTGK_2




sp|P01023|A2MG|HUMAN_AAQVTIQSSGTFSSK_2





sp|P01023|A2MG|HUMAN_NQGNTWLTAFLVK_2





sp|P01023|A2MG|HUMAN_VSVQLEASPAFLAVPVEK_2




sp|P01034|CYTC|HUMAN_ALDFAVGEYNK_2




sp|P01034|CYTC|HUMAN_ALQVVR_2





sp|P01034|CYTC|HUMAN_ASNDMYHSR_2





sp|P02675|FIBB|HUMAN_DNENVVNEYSSELEK_2




sp|P02675|FIBB|HUMAN_EDGGGWYNR_2




sp|P02675|FIBB|HUMAN_QDGSVDFGR_2




sp|P02768-1|ALBU|HUMAN_FQNALLVR_2




sp|P02768-1|ALBU|HUMAN_QNCELFEQLGEYK_2




sp|P02768-1|ALBU|HUMAN_VFDEFKPLVEEPQNLK_3




sp|P02790|HEMO|HUMAN_QGHNSVFLIK_3




sp|P02790|HEMO|HUMAN_SGAQATWTELPWPHEK_3




sp|P02790|HEMO|HUMAN_VWVYPPEK_2




sp|P04083|ANXA1|HUMAN_ALTGHLEEVLLALK_3




sp|P04083|ANXA1|HUMAN_GLGTDEDTLIEILASR_2




sp|P04083|ANXA1|HUMAN_GVDEATIIDLTK_2




sp|P05109|S10A8|HUMAN_ALNSIIDVYHK_2




sp|P05109|S10A8|HUMAN_LLETECPQYIR_2




sp|P05204|HMGN2|HUMAN_LSAKPAPPKPEPKPK_3




sp|P06733-1|ENOA|HUMAN_IGAEVYHNLK_2




sp|P06733-1|ENOA|HUMAN_YISPDQLADLYK_2




sp|P08246|ELNE|HUMAN_LGNGVQCLAMGWLLGR_2




sp|P08246|ELNE|HUMAN_SNVCTLVR_2




sp|P08246|ELNE|HUMAN_VVLGAHNSLR_3




sp|P0C0S8|H2A1|HUMAN_AGLQFPVGR_2




sp|P0C0S8|H2A1|HUMAN_HLQLAIR_2




sp|P0C0S8|H2A1|HUMAN_VTIAQGGVLPNIQAVLLPK_2




sp|P10909-1|CLUS|HUMAN_ASSIIDELFQDR_2




sp|P10909-1|CLUS|HUMAN_EILSVDCSTNNPSQAK_2





sp|P10909-1|CLUS|HUMAN_LFDSDPITVTVPEVSR_2





sp|P14780|MMP9|HUMAN_FGNADGAACHFPFIFEGR_3




sp|P14780|MMP9|HUMAN_QLAEEYLYR_2




sp|P14780|MMP9|HUMAN_QSTLVLPFGDLR_2




sp|P22894|MMP8|HUMAN_SIGAFPGIESK_2




sp|P22894|MMP8|HUMAN_YYAFDLIAQR_2




sp|P23280|CAH6|HUMAN_HVIEIHVHYNSK_3




sp|P23280|CAH6|HUMAN_LENSSLDDHR_2




sp|P23280|CAH6|HUMAN_NYPENTYYSNFISHLANIK_2




sp|P29508-1|SPB3|HUMAN_QYTSFHFASLEDVQAK_3





sp|P29508-1|SPB3|HUMAN_VLHFDQVTENTTGK_3





sp|P31947-1|I433S|HUMAN_GEELSCEER_2





sp|P31947-1|1433S|HUMAN_VLSSIEQK_2





sp|P31947-1|1433S|HUMAN_YLAEVATGDDK_2





sp|P48595|SPB10|HUMAN_AVGLQLYYK_2





sp|P48595|SPB10|HUMAN_IQNLLPDDSDSTTR_2




sp|P48595|SPB10|HUMAN_NLFLSNVFHK_2




sp|P50552|VASP|HUMAN_YNQATPNFHQWR_3




sp|P52566|GDIR2|HUMAN_APEPHVEEDDDDELDSK_3




sp|P52566|GDIR2|HUMAN_APNVVTR_2




sp|P52566|GDIR2|HUMAN_TLLGDPVVTDPK_2




sp|P54108|CRIS3|HUMAN_DPAFTALLTQTQVQR_2




sp|P54108|CRIS3|HUMAN_WANQCNYR_2




sp|P54108|CRIS3|HUMAN_YYVCQYCPAGNWANR_2




sp|P68032|ACTC|HUMAN_AGFAGDDAPR_2




sp|P68032|ACTC|HUMAN_AVFPSIVGRPR_2





sp|P68032|ACTC|HUMAN_SYELPDGQVITIGNER_2





sp|P69905|HBA|HUMAN_FLASVSTVLTSK_2





sp|P69905|HBA|HUMAN_TYFPHDLSHGSAQVK_2





sp|P69905|HBA|HUMAN_VGAHAGEYGAEALER_3




sp|P80723-1|BASP1|HUMAN_ESEPQAAAEPAEAK_2




sp|P80723-1|BASP1|HUMAN_ETPAATEAPSSSTPK_2




sp|Q14019|COTL1|HUMAN_AAYNLVR_2




sp|Q14019|COTL1|HUMAN_LFAFVR_2




sp|Q16610-1|ECM1|HUMAN_ELLALIQLER_2




sp|Q16610-1|ECM1|HUMAN_FCEAEFSVK_2




sp|Q16610-1|ECM1|HUMAN_LTFINDLCGPR_2




sp|Q9NP99-1|TREM1|HUMAN_IILEDYHDHGLLR_3




sp|Q9UGM3-1|DMBT1|HUMAN_CVWDIEVQNNYR_2




sp|Q9UGM3-1|DMBT1|HUMAN_INLGFSNLK_2



zz|ZZ|FGCZCont0031|_DGAGDVAFIR_2



zz|ZZ|FGCZCont0031|_NLLFNDNTECLAR_2



zz|ZZ|FGCZCont0031|_SNLCALCIGDEQGENK_2

